Cyclosporine A demonstrates therapeutic benefits in ulcerative colitis by targeting cellular senescence through JAK2-STAT3/NF-κB pathway inhibition, reducing pro-inflammatory cytokines IL-6, IL-1β, and TNF-α while restoring gut microbiota balance and bile acid metabolism in mouse models. The research employed multi-omics analysis combining network pharmacology, transcriptomics, metabolomics, and metagenomics to map these mechanisms. This finding represents a paradigm shift in understanding inflammatory bowel disease pathogenesis by establishing cellular senescence as a central driver of the condition. The self-amplifying cycle between inflammation and senescence offers a compelling therapeutic target that could benefit the estimated 1.6 million Americans living with IBD. While cyclosporine A is already FDA-approved for other autoimmune conditions, its senescence-targeting properties suggest broader anti-aging applications beyond immune suppression. However, the study's limitation to mouse models requires human validation, and cyclosporine's known nephrotoxicity and infection risks must be weighed against benefits. The gut microbiota restoration, particularly Akkermansia abundance recovery, adds another dimension to this immunosuppressant's therapeutic profile, suggesting precision medicine approaches based on individual microbiome profiles.